The present invention provides a topical composition comprising extract from Coriolus versicolor for use for preventing and/or treating by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infectious agent, in particular, human papiloma virus infections and related disorders, including cervical cancer. The composition of the invention acts enhancing genital immunity against infectious agents and re-epithelising damaged tissue.

Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.

Coronavirus Disease 2019 (COVID-19) remains a threat with the emergence of new variants, especially Delta and Omicron, without specific effective therapeutic drugs. The present invention provides a method and a composition for preventing and treating COVID-19 (SARS-CoV-2) coronavirus infection which includes administering to a subject in need thereof one or more therapeutically effective doses of Virofree which comprises a pharmaceutically acceptable combination of grape seed extract, acerola cherry extract, olive leaf extract, marigold extract, green tea extract, pomegranate extract, yeast beta-glucan and soya bean extract for a treatment period.

The present invention provides an oligodeoxynucleotide which comprises a CpG oligodeoxynucleotide comprising a nucleotide sequence represented by formula (1):

5′X-CpG-L-CpG-TZ3′  (I) wherein X is T or C, L is a nucleotide sequence consisting of 1 to 7 bases, and Z is T or C, and consisting of 8 to 16 bases, and
a polydeoxyadenylic acid having a length capable of forming a complex with a β-1,3-glucan,
wherein the polydeoxyadenylic acid is linked to the 3′ side of the CpG oligodeoxynucleotide.

In addition, the present invention provides a complex containing said oligodeoxynucleotide and a β-1,3-glucan.

The present invention provides an oligodeoxynucleotide which comprises a CpG oligodeoxynucleotide comprising a nucleotide sequence represented by formula (1):

5′X-CpG-L-CpG-TZ3′  (I) wherein X is T or C, L is a nucleotide sequence consisting of 1 to 7 bases, and Z is T or C, and consisting of 8 to 16 bases, and
a polydeoxyadenylic acid having a length capable of forming a complex with a β-1,3-glucan,
wherein the polydeoxyadenylic acid is linked to the 3′ side of the CpG oligodeoxynucleotide.

In addition, the present invention provides a complex containing said oligodeoxynucleotide and a β-1,3-glucan.

Provided is a use of fibers formed of β-1-4-glucan in manufacturing a composition for preventing or treating diarrhea, constipation or irritable bowel syndrome, wherein the fibers have a diameter between 15 nm to 35 nm and a mean length of between 1.5 μm and 3.5 μm. Also provided is a method for preventing or treating diarrhea, constipation or irritable bowel syndrome with the fibers formed of β-1-4-glucan.

Provided is a use of fibers formed of β-1-4-glucan in manufacturing a composition for preventing or treating diarrhea, constipation or irritable bowel syndrome, wherein the fibers have a diameter between 15 nm to 35 nm and a mean length of between 1.5 μm and 3.5 μm. Also provided is a method for preventing or treating diarrhea, constipation or irritable bowel syndrome with the fibers formed of β-1-4-glucan.

Compositions for the treatment, prevention of, proliferation of, or killing of cells associated with metastatic progression of cancer in a cancer patient are disclosed. More specifically, compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. Compositions disclosed herein include formulations of monolaurin, and formulations including monolaurin and additional components. Also, methods of treating metastatic cancer and/or preventing cancer relapse in a cancer patient by administering compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. The compositions and methods disclosed herein are useful for killing circulating cancer cells that cause metastasis and cancer relapse.

Compositions for the treatment, prevention of, proliferation of, or killing of cells associated with metastatic progression of cancer in a cancer patient are disclosed. More specifically, compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. Compositions disclosed herein include formulations of monolaurin, and formulations including monolaurin and additional components. Also, methods of treating metastatic cancer and/or preventing cancer relapse in a cancer patient by administering compositions containing a single type of glyceride, fatty acid, or fatty acid derivative, mixtures thereof, or glycerides and/or fatty acids/fatty acid derivatives in combination with cancer metabolism disruptors, chemotherapeutics and modulators of immune response, are disclosed. The compositions and methods disclosed herein are useful for killing circulating cancer cells that cause metastasis and cancer relapse.

The invention comprises a defined and safe soil substitute, herein referred to as “deconstructed soil”, that supports ecological balance in anaerobic microbial ecosystems, such as that inside the human gut, by shifting energy availability to favor growth of bacteria linked with gut health, and away from the most dominant species and species that are putatively harmful. The invention enables vulnerable bacterial groups to recover from a state of apparent extinction from the ecosystem in question. As it does not contain components that are prebiotic or probiotic, the deconstructed soil represents a new product concept for preventing and treating conditions associated with dysfunctional microbial ecosystems in the gastrointestinal tract of humans and animals, as well as other anaerobic microbial ecosystems.